CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
28.15 USD   -1.68%
06/15CEREVEL THERAPEUTICS : Announces Updates to its Board of Directors - Form 8-K
PU
06/15CEREVEL THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
06/15Cerevel Therapeutics Announces Updates to its Board of Directors
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
23.92(c) 25.21(c) 26.21(c) 28.63(c) 28.15(c) Last
850 244 544 095 331 943 415 238 1 796 671 Volume
+4.45% +5.39% +3.97% +9.23% -1.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -283 M - -
Net cash position 2022 218 M - -
P/E ratio 2022 -14,5x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -327 M - -
Net cash position 2023 71,9 M - -
P/E ratio 2023 -12,8x
Yield 2023 -
Capitalization 4 174 M 4 174 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 228
Free-Float 81,4%
More Financials
Company
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including... 
More about the company
Ratings of Cerevel Therapeutics Holdings, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
06/15CEREVEL THERAPEUTICS : Announces Updates to its Board of Directors - Form 8-K
PU
06/15CEREVEL THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Amendment..
AQ
06/15Cerevel Therapeutics Announces Updates to its Board of Directors
AQ
06/15Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors
CI
05/25Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
AQ
05/24Goldman Sachs Adjusts Cerevel Therapeutics Holdings' Price Target to $20 from $28, Keep..
MT
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Main..
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
05/10Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ende..
CI
05/10Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
AQ
04/18INSIDER SELL : Cerevel Therapeutics Holdings
MT
04/13Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update..
AQ
04/08SIRS 2022 PRESENTATION – EMRAC : Results From a Phase 1b Trial in Patients With Schi..
PU
04/06AAN 2022 POSTER - PHARMACOKINETICS, : Summary of Early Phase Clinical Studies
PU
More news
News in other languages on CEREVEL THERAPEUTICS HOLDINGS, INC.
06/15Cerevel Therapeutics nomme Suneet Varma comme membre de son conseil d'administration
05/10Cerevel Therapeutics Holdings, Inc. annonce ses résultats pour le premier trimestre clo..
03/11VENTE D'INITIÉS : Cerevel Therapeutics Holdings
03/01La perte du quatrième trimestre de Cerevel Therapeutics s'accentue ; l'entreprise s'att..
03/01Cerevel Therapeutics Holdings, Inc. annonce ses résultats pour le quatrième trimestre e..
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 28,15 $
Average target price 41,71 $
Spread / Average Target 48,2%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-13.17%4 174
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574